At least two sponsors will submit accelerated approval pathway applications to FDA for psilocybin-based therapies by November 2027

Psilocybin therapy companies have good clinical trial data on depression and suicidal thoughts. Two of them will ask the FDA (US drug regulator) for an expedited approval process called 'accelerated approval,' which is faster than normal. But the FDA may say no because of how hard it is to run psilocybin trials fairly.

RCT data on MDD, suicidal ideation, and cocaine use disorder constitutes a meaningful evidentiary advance, but accelerated approval requires demonstration of effect on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit — psilocybin trials have historically struggled with blinding and endpoint standardization issues that complicate accelerated approval specifically. Sponsors have strong commercial incentives to file, but FDA's 2023-2025 signals on psychedelic accelerated approval have been cautious. Confidence reduced from original to reflect genuine regulatory friction.